We are preparing a lecture series to teach scientist in different field how to use our complete proprietary VADEX technology. Each scientist who are interested in using VADEX technology to generate ultra-high affinity monoclonal antibody ( KD<1E-12 M) can registers and obtains a voucher for future redeem of a sublicense of our patent after you successfully develop your monoclonal antibody derived products. Each voucher is good for a single target protein as defined by UniProt ID. The registration slot for first year will be limited to 200. Vaxsia only provides up to three sublicenses for each UniProt ID. And the licensing deal is sweet, with 10,000 USD annual fee and 1% revenue. Further announcements will be made soon.
Month: November 2026
PCT application published
Vaxsia Biomed Inc. announces the publication of PCT application.
PCT/IB2026/000173